Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × lorlatinib × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Lymphoid 1

Conditions

Thrombocytosis 1 Recurrence 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Breast Neoplasms 1 Blast Crisis 1 Anemia 1

Interventions

Cyclophosphamide 88 Rituximab 67 Peripheral Blood Stem Cell Transplantation 36 fludarabine 35 fludarabine phosphate 34 Filgrastim 31 Lenalidomide 29 Radiotherapy 26 Cyclosporine 26 Busulfan 26 Methotrexate 25 Melphalan 25 Etoposide 25 Cytarabine 25 venetoclax 24 Mycophenolic Acid 23 Dexamethasone 22 Gemcitabine 21 Bendamustine Hydrochloride 20 Antilymphocyte Serum 20 ibrutinib 19 Whole-Body Irradiation 19 Vincristine 17 Methylprednisolone 16 pembrolizumab 15 Tacrolimus 15 Doxorubicin 14 Brentuximab Vedotin 14 Bortezomib 14 Granulocyte Colony-Stimulating Factor 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03505554 2023-08-07

CRU3

University of Milano Bicocca

Phase 2 Unknown

Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡